Login
Home
Charts
Search
Watchlist
Products

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM·NSE
₹225.63-0.02%Wed, 23 Sept '26 15:58
Industry:Pharma - API
Indices:

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM
NSE
₹225.63
-0.02%
|Wed, 23 Sept '26 15:58
SOICxStockScans Reports
Industry
Pharma - API
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹1,503Cr
Close
Close Price
₹227.90
Industry
Industry
Pharma - API
PE
Price To Earnings
33.51
PS
Price To Sales
5.12
Revenue
Revenue
₹294Cr
Rev Gr TTM
Revenue Growth TTM
3.87%
PAT Gr TTM
PAT Growth TTM
-25.25%

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
584743617574597674736482
Growth YoY
Revenue Growth YoY%
-4.5-21.5-21.62.129.156.734.623.1-0.3-1.59.68.8
Expenses
ExpensesCr
494441515858506158575365
Operating Profit
Operating ProfitCr
83310161691416161117
OPM
OPM%
14.57.26.116.721.821.414.918.822.122.317.421.0
Other Income
Other IncomeCr
232-2226333133
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000122222222
PBT
PBTCr
10557153991417151218
Tax
TaxCr
211247244434
PAT
PATCr
744511327111311913
Growth YoY
PAT Growth YoY%
-28.2-49.2-36.6-28.753.4707.885.3102.69.7-65.833.122.1
NPM
NPM%
12.98.48.28.715.343.211.214.316.915.013.616.0
EPS
EPS₹
1.10.60.50.80.71.91.01.61.91.71.32.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
584743617574597674736482
Growth YoY
Revenue Growth YoY%
-4.5-21.5-21.62.129.156.734.623.1-0.3-1.59.68.8
Expenses
ExpensesCr
494441515858506158575365
Operating Profit
Operating ProfitCr
83310161691416161117
OPM
OPM%
14.57.26.116.721.821.414.918.822.122.317.421.0
Other Income
Other IncomeCr
232-2226333133
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000122222222
PBT
PBTCr
10557153991417151218
Tax
TaxCr
211247244434
PAT
PATCr
744511327111311913
Growth YoY
PAT Growth YoY%
-28.2-49.2-36.6-28.753.4707.885.3102.69.7-65.833.122.1
NPM
NPM%
12.98.48.28.715.343.211.214.316.915.013.616.0
EPS
EPS₹
1.10.60.50.80.71.91.01.61.91.71.32.0

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
143144127167159188218237209269287294
Growth
Revenue Growth%
3.90.3-12.131.8-5.018.515.88.8-11.828.86.93.9
Expenses
ExpensesCr
132138138157150169193203186218229233
Operating Profit
Operating ProfitCr
126-119919253423515861
OPM
OPM%
8.24.0-8.85.65.410.211.514.411.119.020.220.8
Other Income
Other IncomeCr
1130134329281010
Interest Expense
Interest ExpenseCr
531111001111
Depreciation
DepreciationCr
320111212899
PBT
PBTCr
414-129922273530705861
Tax
TaxCr
130225887151415
PAT
PATCr
312-127817192722554345
Growth
PAT Growth%
177.9264.6-197.3162.59.1116.710.541.7-15.9146.4-22.2-25.3
NPM
NPM%
2.38.3-9.14.35.09.18.711.310.820.615.015.5
EPS
EPS₹
0.51.8-1.81.11.22.62.94.13.48.36.46.8
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
143144127167159188218237209269287294
Growth
Revenue Growth%
3.90.3-12.131.8-5.018.515.88.8-11.828.86.93.9
Expenses
ExpensesCr
132138138157150169193203186218229233
Operating Profit
Operating ProfitCr
126-119919253423515861
OPM
OPM%
8.24.0-8.85.65.410.211.514.411.119.020.220.8
Other Income
Other IncomeCr
1130134329281010
Interest Expense
Interest ExpenseCr
531111001111
Depreciation
DepreciationCr
320111212899
PBT
PBTCr
414-129922273530705861
Tax
TaxCr
130225887151415
PAT
PATCr
312-127817192722554345
Growth
PAT Growth%
177.9264.6-197.3162.59.1116.710.541.7-15.9146.4-22.2-25.3
NPM
NPM%
2.38.3-9.14.35.09.18.711.310.820.615.015.5
EPS
EPS₹
0.51.8-1.81.11.22.62.94.13.48.36.46.8

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
1313131313131313131313
Reserves
ReservesCr
8597859198109120146174226261
Current Liabilities
Current LiabilitiesCr
5729292833402728192628
Non Current Liabilities
Non Current LiabilitiesCr
43333248111212
Total Liabilities
Total LiabilitiesCr
159143130136147164164195217278317
Current Assets
Current AssetsCr
101110959895120109165197161143
Non Current Assets
Non Current AssetsCr
583335385244553020117174
Total Assets
Total AssetsCr
159143130136147164164195217278317
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
1313131313131313131313
Reserves
ReservesCr
8597859198109120146174226261
Current Liabilities
Current LiabilitiesCr
5729292833402728192628
Non Current Liabilities
Non Current LiabilitiesCr
43333248111212
Total Liabilities
Total LiabilitiesCr
159143130136147164164195217278317
Current Assets
Current AssetsCr
101110959895120109165197161143
Non Current Assets
Non Current AssetsCr
583335385244553020117174
Total Assets
Total AssetsCr
159143130136147164164195217278317

Cash Flow

Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
9-3-2311128747355547
Investing Cash Flow
Investing Cash FlowCr
-241-3-1-11-2-26-58-25-45-36
Financing Cash Flow
Financing Cash FlowCr
-6-34-1-6-1-7-180-9-12-12
Net Cash Flow
Net Cash FlowCr
15-624019-36-112-2-1
Free Cash Flow
Free Cash FlowCr
940-1321428648359047
CFO To PAT
CFO To PAT%
277.8-27.313.6428.2142.9165.436.7174.6156.699.5108.7
CFO To EBITDA
CFO To EBITDA%
76.5-56.214.2331.0131.8147.927.6136.6152.4107.980.6
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
9-3-2311128747355547
Investing Cash Flow
Investing Cash FlowCr
-241-3-1-11-2-26-58-25-45-36
Financing Cash Flow
Financing Cash FlowCr
-6-34-1-6-1-7-180-9-12-12
Net Cash Flow
Net Cash FlowCr
15-624019-36-112-2-1
Free Cash Flow
Free Cash FlowCr
940-1321428648359047
CFO To PAT
CFO To PAT%
277.8-27.313.6428.2142.9165.436.7174.6156.699.5108.7
CFO To EBITDA
CFO To EBITDA%
76.5-56.214.2331.0131.8147.927.6136.6152.4107.980.6

Ratios

Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
861007069462088227597431,4341,2341,503
Price To Earnings
Price To Earnings
26.88.49.65.812.243.628.432.925.928.733.5
Price To Sales
Price To Sales
0.60.70.60.40.31.13.83.23.65.34.35.1
Price To Book
Price To Book
0.91.00.80.70.41.86.24.84.06.04.55.5
EV To EBITDA
EV To EBITDA
9.215.2-5.83.71.48.131.819.126.225.719.622.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
56.056.650.255.063.956.558.860.861.564.063.563.5
OPM
OPM%
8.24.0-8.85.65.410.211.514.411.119.020.220.8
NPM
NPM%
2.38.3-9.14.35.09.18.711.310.820.615.015.5
ROCE
ROCE%
6.814.5-10.39.08.617.420.321.415.628.520.720.7
ROE
ROE%
3.310.8-11.86.97.114.014.216.812.023.115.715.7
ROA
ROA%
2.08.3-8.95.35.410.411.513.710.319.913.613.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
861007069462088227597431,4341,2341,503
Price To Earnings
Price To Earnings
26.88.49.65.812.243.628.432.925.928.733.5
Price To Sales
Price To Sales
0.60.70.60.40.31.13.83.23.65.34.35.1
Price To Book
Price To Book
0.91.00.80.70.41.86.24.84.06.04.55.5
EV To EBITDA
EV To EBITDA
9.215.2-5.83.71.48.131.819.126.225.719.622.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
56.056.650.255.063.956.558.860.861.564.063.563.5
OPM
OPM%
8.24.0-8.85.65.410.211.514.411.119.020.220.8
NPM
NPM%
2.38.3-9.14.35.09.18.711.310.820.615.015.5
ROCE
ROCE%
6.814.5-10.39.08.617.420.321.415.628.520.720.7
ROE
ROE%
3.310.8-11.86.97.114.014.216.812.023.115.715.7
ROA
ROA%
2.08.3-8.95.35.410.411.513.710.319.913.613.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
- **Jagsonpal Pharmaceuticals is a specialty pharmaceutical company that sells branded prescription medicines almost entirely in India - it does not manufacture anything itself. What began in 1964 has, over decades, become a business trusted by more than 50,000 doctors, built on an asset-light model where the company invents the drug concepts in-house but outsources all production to contract manufacturers. The recurring approach is to pick a mid-sized, sub-chronic therapy area - gynaecology, orthopaedics, dermatology, paediatrics - and aim for a top-five ranking in that narrow segment, avoiding the crowded chronic-disease market where doctor incentives are common.** # Business segments A single engine - a portfolio of 75-plus branded prescription products sold through a dedicated field force to doctors across four therapy areas, with all manufacturing outsourced. ## 1. Branded formulations: a house of niche prescription brands **The company owns over 75 branded drugs, nine of its top ten ranked in the top five of their categories, and sells them entirely on prescription through a 1,000-strong sales force - it is a marketing and distribution engine, not a factory.** - **Hormonal products are the moat** - more than half of sales come from hormonal drugs, which require deep doctor engagement and trust to prescribe, so once a doctor adopts the brand, switching is rare. - **Mostly free to raise prices** - 92% of the portfolio sits outside the National List of Essential Medicines, meaning the company can increase prices by up to 9.9% a year on those products without government approval. - **Gynaecology is the anchor** - the company reaches roughly 90% of India's gynaecologists (35,000 out of 39,000) and ranks seventh in the therapy area, with leadership in the progesterone segment and a Dydrogesterone brand, Divatrone, that became its largest product within 18 months of launch. - **Orthopaedics is the second pillar** - it reaches about 80% of orthopaedists and holds the number-two rank in the therapy area, led by Indocap, the flagship brand that was the first to cross ₹500 million in revenue. - **Dermatology and paediatrics were bought, not built** - the 2024 acquisition of Yash Pharma added 33 brands, a field force of roughly 225 people, and access to dermatology and childcare markets worth approximately ₹200 billion, lifting the company's IQVIA rank by 18 places. # Sales force and distribution **A field force of about 1,000 medical representatives generates prescriptions from over 50,000 doctors, and 1,200-plus distributors push the products to more than 125,000 pharmacies across 4,000-plus towns.** - **Doctors are the only customer that matters** - all sales happen through prescriptions, so the company measures its business by MR productivity, doctor coverage, and call quality, not consumer advertising. - **Three therapy-specific divisions** - the sales force was restructured into Boneva (orthopaedics), Fembon (gynaecology), and Naari (gynaecology) so each unit focuses on a single doctor speciality and its prescribing habits. - **A lean supply chain with no factories** - 18 stocking points feed a network of 1,200-plus distributors, and the company switched from its own depots to a carrying-and-forwarding-agent model to cut costs and get closer to customers. - **The hospital channel is the newest front** - in mid-2026 the company bought a 69.77% stake in Aequitas Healthcare, a Mumbai-based hospital-supply distributor, marking its first entry into institutional sales. # Group structure and partners **The company is standalone, debt-free, and jointly controlled by a Mauritius-based investment group and the founding family, with no subsidiaries until the Aequitas acquisition closed in July 2026.** - **Two promoters, one board** - Infinity Holdings holds 43.73% and the Kochhar family retains 24.99%, with a shareholders' agreement giving Infinity the right to nominate the Managing Director. - **Acquisitions are the growth lever** - the Yash Pharma deal (2024) added dermatology and paediatrics, and the Aequitas deal (2026) opened the hospital channel, both paid in cash from internal accruals without taking on debt. - **No manufacturing subsidiaries** - the company sold its only plant, in Faridabad, for ₹410 million (₹41 crores); it was already non-operational and contributed no revenue.

Documents — Jagsonpal Pharmaceuticals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/j91qcfjpy2rykowcjk27lpr7.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/1nobfaj6ayfdkho9jbkl1cek.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/90aq8qpouxg3l2qy8c88p7f5.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/vozpz4yl5kddhhpwsgvq5iwl.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/d6hg8ern9tb3hgaia02rs182.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/dzbve8srfcrwijqoann5el4h.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/7obslwl25q4a2ulw00qe14ay.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/jnf7sdzqht8kgtx0ujhkurjz.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/zv9p39wjhpx0lqsfhov1cjvy.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/51tdtyr8rlohne01j0hl2sks.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/ifgazipgjbxxg68d1mfq9kh5.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/r99yoyf9e1x9jwr5fpyi9k1w.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/tqgf1hcyb8a09xpyrqw00nwa.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/kqjtr7lnfpt3mxbjq10j3nj4.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/2s60rp2r9yhun8r8x52bt3qn.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/lgmw8p986rtfkium79sypt07.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/e5gaoo7hakjjd7ndetnaqlj7.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/4tvk688gkd7llq5uwxjbovej.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/28jh2i3embrv15ov35cagpzl.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/9z6i7z9ak9e9f5gz9n7j6etd.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/j2nevq2duuj8h7lq46x0g73j.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/08aknxy20ojwco3gb47kxu5z.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/3yno6q43e3kfin6kwlflg5ho.pdf
  • Q1 FY2025 Investor Presentation (Jun 2024, PDF): https://www.stockscans.in/document/v8nksabmz7sc1pxuww0h3iu1.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/boj1cqtbydhflvj8ecielkt9.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/du7tzk4c5ymwto2og7f58nfc.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/1jsdqmaqz8a0tncxfz46z53d.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/jvryw7n930jstqcd41i5b0k6.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/c2qu4vc42y9ux3r7i0yk5svx.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/27t6jbwu1l9zv2cfpy4yjfet.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/zekccnj4k0w0wpa7llj2fshw.pdf

Concall Transcript Summaries — Jagsonpal Pharmaceuticals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202606/j91qcfjpy2rykowcjk27lpr7.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202603/1nobfaj6ayfdkho9jbkl1cek.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202512/90aq8qpouxg3l2qy8c88p7f5.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202509/vozpz4yl5kddhhpwsgvq5iwl.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202506/d6hg8ern9tb3hgaia02rs182.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202503/dzbve8srfcrwijqoann5el4h.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202412/7obslwl25q4a2ulw00qe14ay.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AJAGSNPHARM/transcript-notes/202409/jnf7sdzqht8kgtx0ujhkurjz.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies